• Contact Us

• Press Releases
• Press Release Archives
• Events

Press Releases Archives

• 12/15/10
  Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients with Refractory Metastatic Colorectal Cancer
• 11/17/10
  Jennerex Appoints Barry Sherman, M.D. to Board of Directors
• 10/21/10
  Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
• 09/13/10
  Jennerex Presents Positive Interim Data Using JX-594 and Sorafenib to Treat Liver Cancer
• 09/7/10
  Jennerex and Transgene Enter into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
• 08/25/10
  Jennerex Appoints Lara Longpre to Chief Operating Officer
• 08/19/10
  Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
• 06/22/10
  Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
• 05/20/10
  Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
• 05/13/10
  Key Clinical Data Regarding Jennerex's JX-594 to be Featured at American Society of Gene and Cell Therapy Meeting
• 04/28/10
  Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
• 04/19/10
  Positive Interim Results for JX-594 Randomized Phase 2 Liver Cancer Trial Presented at Major International Conference (EASL)
• 04/13/10
  Jennerex Completes Patient Enrollment in Phase 1 Trial for Intravenous Administration of JX-594
• 01/11/10
  Jennerex Appoints Dr. Hoyoung Huh to Its Board of Directors
• 12/23/09
  Jennerex Announces Presentations at Upcoming Conferences
• 11/18/09
  Jennerex and Lee's Pharmaceuticals Announce Partnership jor JX-594 in China
• 10/19/09
  Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
• 09/18/09
  Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
  Clinical Trial Programs with Lead Product Jx-594 Funded Through 2010
• 08/11/09
  Jennerex Closes $5 Million First Tranche of Series C Financing
  Clinical Trial Programs Funded Through 2010
• 06/11/09
  Jennerex Therapeutic Research Collaboration with Ottawa Hospital Research Institute Selected for $10 Million Grant from Ontario Institute for Cancer Research
• 02/10/09
  Nature Reviews Publishes Article about Jennerex's Multi-mechanistic Cancer Therapeutic
• 01/13/09
  Jennerex Appoints Samantha Miller as Vice President of Corporate Development
• 01/12/09
  Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
• 11/04/08
  Jennerex To Present at Rodman & Renshaw 10th Annual Healthcare Conference
• 10/15/08
  Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial with Intravenous Delivery of JX-594 Oncolytic Virus
• 09/09/08
  Jennerex Completes $8.3 Million Series B Financing and Appoints
  Dr. Cal Stiller as Director
• 07/16/08
  Jennerex Publishes Clinical Trial Data with Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated
  Hepatitis B Virus
• 06/02/08
  Jennerex Clinical Trial Data with JX-594 Selected for Plenary Session Presentation at Major International Conference
• 05/21/08
  Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
• 11/08/07
  Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
• 10/23/07
  Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
• 10/17/06
  Jennerex and Green Cross Enter Agreement to Develop and Commercialize JX-594 In South Korea